Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The development of selective inhibitors of monoamine oxidase B (MAO-B) has been essential in treating Parkinson's disease.
|
31639490 |
2020 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results suggest that such compounds may be utilized for the development of new candidate MAO-B inhibitors for treatment of Parkinson's disease.
|
31146671 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rasagiline mesylate is an irreversible MAO-B inhibitor which requires daily oral administration for treatment of Parkinson's disease due to its short half-life.
|
30877626 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
MAO-B-specific inhibitors such as some of the quinazolinone compounds investigated here may act as leads for the design of therapies for neurodegenerative disorders such as Parkinson's disease.
|
31115748 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The irreversible monoamine oxidase B (MAO B) inhibitor rasagiline has been described with multiple disease modifying effects in vitro on models of Parkinson's disease.
|
31421966 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we aimed to explore the antidepressant-like effects of propargyl MAO-B inhibitors, selegiline and rasagiline, in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as a PD model, and to elucidate the mechanisms underlying these effects.
|
31427934 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The current pharmacological treatments for Parkinson's disease only offer symptomatic relief to the patients and are based on the administration of levodopa and catechol-O-methyltransferase or monoamine oxidase-B inhibitors (IMAO-B).
|
31336891 |
2019 |
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.
|
30386930 |
2019 |
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
<b>:</b> Accumulative evidence indicated that the pathologically accumulated metal ions (iron species and Mn<sup>3+</sup>) and abnormally up-regulated monoamine oxidase B (MAOB) activity induced oxidation of endogenous dopamine (DA) can lead to mitochondria impairment, lysosome dysfunction, proteasome inhibition, and selective DA neuron vulnerability, which is implicated in the pathogenesis of Parkinson's disease (PD).
|
31426448 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Monoamine oxidase B (MAO-B) inhibitors have an established role in the treatment of Parkinson's disease as monotherapy or adjuvant to levodopa.
|
31562557 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
MAO-B specific inhibitors such as those discovered here may be of interest in the treatment of neurodegenerative disorders such as Parkinson's disease.
|
31537422 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Introduction</b>: Selective monoamine oxidase-B (MAO-B) inhibitors are currently used as coadjuvants for the treatment of early motor symptoms in Parkinson's disease.
|
31268358 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
|
31005056 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rasagiline is a monoamine oxidase B inhibitor with demonstrated efficacy and safety in patients with Parkinson's disease (PD).
|
30689042 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Good potency MAO-B inhibitors may act as leads for the design and development of therapy for Parkinson's disease where these agents reduce the central metabolism of dopamine.
|
30666491 |
2019 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Selegiline, an irreversible inhibitor of monoamine oxidase (MAO)-type B, is widely prescribed for Parkinson's disease and, at higher doses, for major and atypical depression, whereby it is non-selectively inhibitory to both MAO-A and MAO-B activities.
|
30359642 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, phenylisoxazole carbohydrazides can be promising leads in the development of potent, selective and reversible MAO-B inhibitors for the treatment of Parkinson's disease.
|
30731360 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibition of MAO-B has been an effective strategy for the treatment of Parkinson's disease.
|
30833108 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Irreversible monoamine oxidase-B inhibitors slowed the progression of neuronal dying in experimental models of Parkinson's disease.
|
31017021 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition to the symptomatic benefits offered by MAO-B inhibitors, these drugs may also possess neuroprotective properties and possibly delay the progression of Parkinson's disease.
|
30599413 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Human monoamine oxidase B (MAO-B) catalyzes the oxidation of amines and is inhibited for the treatment of both Parkinson's disease and depression.
|
30964996 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The introduction of MAOB-I in the overall treatment of PD as part of routine clinical practice has not helped to reduce annual mean LED.
|
30963543 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rasagiline is a monoamine oxidase type-B inhibitor in development in Japan for Parkinson's disease (PD).
|
30635744 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Monoamine oxidase type B inhibitors act in Parkinson's disease (PD) via potentiation of dopamine, but may also have neuroprotective effects by reducing oxidative damage.
|
31836905 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rasagiline is a monoamine oxidase type-B inhibitor in development in Japan for Parkinson's disease (PD).
|
30205936 |
2019 |